Hengrui Pharmaceutical announced that the company received the “Drug Clinical Trial Approval Notice” for Revelumide tablets approved and issued by the State Drug Administration and agreed to carry out phase III clinical research on revivalamide combined with androgen deprivation therapy compared with placebo combined with androgen deprivation therapy to treat high-risk localized or high-risk biochemically recurrent prostate cancer after radical surgery/radiotherapy, and will conduct trials in the near future. Revelumide tablets are second-generation AR inhibitors. They were approved and marketed in 2022 to treat patients with high tumor load metastatic hormone-sensitive prostate cancer. Up to now, the total R&D investment for related projects is about 740 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.